Jill Tinmouth1, Pauline Henry2, Eugene Hsieh2, Nancy N Baxter3, Robert J Hilsden4, S Elizabeth McGregor5, Lawrence F Paszat6, Arlinda Ruco7, Refik Saskin8, Andrew J Schell9, Emina E Torlakovic10, Linda Rabeneck11. 1. 1] Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada [2] Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 2. 1] Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada [2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 3. 1] Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada [2] Department of Surgery, University of Toronto, Toronto, Ontario, Canada [3] Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 4. Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. 5. 1] Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada [2] Alberta Health Services Cancer Care, Calgary, Alberta, Canada. 6. 1] Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada [2] Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada [3] Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada [4] Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada [5] Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 7. Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 8. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 9. 1] Calgary Laboratory Services, Calgary, Alberta, Canada [2] Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. 10. 1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada [2] Department of Pathology, UHN Toronto General Hospital, Toronto, Ontario, Canada. 11. 1] Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada [2] Cancer Care Ontario, Toronto, Ontario, Canada [3] Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada [4] Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada [5] Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Abstract
OBJECTIVES: The sessile serrated adenoma/polyp (SSA/P) is increasingly recognized as an important precursor to colorectal cancer (CRC) and may contribute to proximal postcolonoscopy CRCs. Hyperplastic polyps (HPs) generally follow a more benign course than do SSA/Ps, but they have a similar histologic appearance. Our aims were to identify patient and polyp factors associated with reclassification of HPs as SSA/Ps during a central pathology review and to characterize and compare their subsequent clinical management with other polyps. METHODS: From 2003 to 2008, we prospectively enrolled asymptomatic persons aged 50-74 years in a study of screening colonoscopy. Because criteria for SSA/P diagnosis evolved over our study period, we initiated a second review of all HPs >5 mm in size in 2011, with reclassification of polyps if indicated. Rates of subsequent colonoscopies, polypectomies, and CRCs were identified. RESULTS: We enrolled 2,527 persons who underwent colonoscopy in whom 111 had HPs >5 mm. Thirty-two of the 111 participants (28.8%) with HPs >5 mm had their polyps reclassified as SSA/Ps. There were no significant differences in patient characteristics between those with reclassified SSA/Ps and those who had HPs >5 mm. SSA/Ps were more likely to be proximal (P<0.001) and larger (P<0.007) than the HPs. In all, 48.3% of those with high-risk adenomas received appropriate follow-up compared with 26.1% of those with high-risk SSA/Ps. CONCLUSIONS: Almost 1/3 of recently diagnosed HPs >5 mm were reclassified as SSA/Ps. Patients previously diagnosed with larger HPs in the proximal colon may benefit from a pathologic review to ensure appropriate diagnosis and follow-up.
OBJECTIVES: The sessile serrated adenoma/polyp (SSA/P) is increasingly recognized as an important precursor to colorectal cancer (CRC) and may contribute to proximal postcolonoscopy CRCs. Hyperplastic polyps (HPs) generally follow a more benign course than do SSA/Ps, but they have a similar histologic appearance. Our aims were to identify patient and polyp factors associated with reclassification of HPs as SSA/Ps during a central pathology review and to characterize and compare their subsequent clinical management with other polyps. METHODS: From 2003 to 2008, we prospectively enrolled asymptomatic persons aged 50-74 years in a study of screening colonoscopy. Because criteria for SSA/P diagnosis evolved over our study period, we initiated a second review of all HPs >5 mm in size in 2011, with reclassification of polyps if indicated. Rates of subsequent colonoscopies, polypectomies, and CRCs were identified. RESULTS: We enrolled 2,527 persons who underwent colonoscopy in whom 111 had HPs >5 mm. Thirty-two of the 111 participants (28.8%) with HPs >5 mm had their polyps reclassified as SSA/Ps. There were no significant differences in patient characteristics between those with reclassified SSA/Ps and those who had HPs >5 mm. SSA/Ps were more likely to be proximal (P<0.001) and larger (P<0.007) than the HPs. In all, 48.3% of those with high-risk adenomas received appropriate follow-up compared with 26.1% of those with high-risk SSA/Ps. CONCLUSIONS: Almost 1/3 of recently diagnosed HPs >5 mm were reclassified as SSA/Ps. Patients previously diagnosed with larger HPs in the proximal colon may benefit from a pathologic review to ensure appropriate diagnosis and follow-up.
Authors: Sahana Arumugam; Chantal M C le Clercq; Robert G Riedl; Ad A M Masclee; Silvia Sanduleanu Journal: Am J Gastroenterol Date: 2015-01 Impact factor: 10.864
Authors: Ronald G Racho; Murli Krishna; Susan G Coe; Colleen S Thomas; Julia E Crook; Nancy N Diehl; Michael B Wallace Journal: Dig Dis Sci Date: 2017-04-25 Impact factor: 3.199
Authors: Chun-Han Lo; Long H Nguyen; Kana Wu; Shuji Ogino; Andrew T Chan; Edward L Giovannucci; Mingyang Song Journal: Cancer Prev Res (Phila) Date: 2020-08
Authors: Douglas K Rex; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; Theodore R Levin; David Lieberman; Douglas J Robertson Journal: Am J Gastroenterol Date: 2017-06-06 Impact factor: 10.864
Authors: Rebecca A Gourevitch; Sherri Rose; Seth D Crockett; Michele Morris; David S Carrell; Julia B Greer; Reetesh K Pai; Robert E Schoen; Ateev Mehrotra Journal: Am J Gastroenterol Date: 2018-01-30 Impact factor: 10.864
Authors: Vikram Deshpande; Richard O Hynes; Steffen Rickelt; Charlene Condon; Miyeko Mana; Charlie Whittaker; Christina Pfirschke; Jatin Roper; Deepa T Patil; Ian Brown; Anthony R Mattia; Lawrence Zukerberg; Qing Zhao; Runjan Chetty; Gregory Y Lauwers; Azfar Neyaz; Lieve G J Leijssen; Katherine Boylan; Omer H Yilmaz Journal: Clin Cancer Res Date: 2019-12-18 Impact factor: 12.531